scholarly journals Population Genetics Based Phylogenetics Under Stabilizing Selection for an Optimal Amino Acid Sequence: A Nested Modeling Approach

2017 ◽  
Author(s):  
Jeremy M. Beaulieu ◽  
Brian C. O’Meara ◽  
Russell Zaretzki ◽  
Cedric Landerer ◽  
Juanjuan Chai ◽  
...  

AbstractWe present a new phylogenetic approach SelAC (Selection on Amino acids and Codons), whose substitution rates are based on a nested model linking protein expression to population genetics. Unlike simpler codon models which assume a single substitution matrix for all sites, our model more realistically represents the evolution of protein coding DNA under the assumption of consistent, stabilizing selection using cost-benefit approach. This cost-benefit approach allows us generate a set of 20 optimal amino acid specific matrix families using just a handful of parameters and naturally links the strength of stabilizing selection to protein synthesis levels, which we can estimate. Using a yeast dataset of 100 orthologs for 6 taxa, we find SelAC fits the data much better than popular models by 104–105 AICc units. Our results indicate there is great potential for more accurate inference of phylogenetic trees and branch lengths from already existing data through the use of nested, mechanistic models. Additional parameters estimated by SelAC indicate that a large amount of non-phylogenetic, but biologically meaningful, information can be inferred from exisiting data. For example, SelAC prediction of gene specific protein synthesis rates correlates well with both empirical (r=0.33−0.48) and other theoretical predictions (r=0.45−0.64) for multiple yeast species. SelAC also provides estimates of the optimal amino acid at each site. Finally, because SelAC is a nested approach based on clearly stated biological assumptions, future modifications, such as including shifts in the optimal amino acid sequence within or across lineages, are possible.

2018 ◽  
Vol 36 (4) ◽  
pp. 834-851 ◽  
Author(s):  
Jeremy M Beaulieu ◽  
Brian C O’Meara ◽  
Russell Zaretzki ◽  
Cedric Landerer ◽  
Juanjuan Chai ◽  
...  

1977 ◽  
Author(s):  
F.J. Morgan ◽  
G.S. Begg ◽  
C.N. Chesterman

The amino acid sequence of human platelet factor 4 (PF4) has been studied. PF4 is a platelet specific protein with antiheparin activity, released from platelets as a proteoglycan complex, whose measurement may provide an important index of platelet activation both in vivo and in vitro. These studies were undertaken to characterize fully the PF4 molecule. PF4 is a stable tetramer, composed of identical subunits, each with a molecular weight based on the sequence studies of approx. 7,770. Each PF4 subunit contains 69 amino acids, including 4 half-cystine (# 10, 12, 36, 37), one tyrosine (# 59), 3 arginine and 8 lysine, but no methionine, phenylalanine or tryptophan residues. The basic residues are predominantly in the C-terminal region. The tryptic peptides were aligned after studies which included tryptic digestion of citraconylated RCM-PF4, and automated Edman degradation of RCM-PF4 and citraconylated tryptic peptides. No glycopeptides were detected. This structural information should enable clear distinction to be made between PF4 and other platelet proteins such as β thromboglobulin. The provisional amino acid sequence of each subunit is:Glu-Ala-Glu-Glu-Asp-Gly-Asp-Leu-Gln-Cys-Leu-Cys-Val-Lys-Thr-Thr-Ser-Gln-Val-Arg-Pro-Arg-His-Ile-Thr-Ser-Leu-Glu-Val-Ile-Lys-Ala-Gly-Pro-His-Cys-Cys-Pro-Thr-Ala-Gln-Ile-Leu-Ala-Thr-Leu-Lys-Asn-Gly-Arg-Lys-Ile-Pro-Leu-Asp-Leu-Gln-Ala-Tyr-Leu-Lys-Ile-Lys(Lys, Lys, Ser, Glx, Leu, Leu)


1987 ◽  
Vol 169 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Muriel CHAUVIERE ◽  
Arlette MARTINAGE ◽  
Gilbert BRIAND ◽  
Pierre SAUTIERE ◽  
Philippe CHEVAILLIER

1998 ◽  
Vol 62 (6) ◽  
pp. 1152-1156 ◽  
Author(s):  
Yuji MINAMI ◽  
Ken-ichi YAMAGUCHI ◽  
Fumio YAGI ◽  
Kenjiro TADERA ◽  
Gunki FUNATSU

2007 ◽  
Vol 27 (1-3) ◽  
pp. 5-9 ◽  
Author(s):  
Salvatore DiMauro

The small, maternally inherited mitochondrial DNA (mtDNA) has turned out to be a hotbed of pathogenic mutations: 15 years into the era of ‘mitochondrial medicine’, over 150 pathogenic point mutations and countless rearrangements have been associated with a variety of multisystemic or tissue-specific human diseases. MtDNA-related disorders can be divided into two major groups: those due to mutations in genes affecting mitochondrial protein synthesis in toto and those due to mutations in specific protein-coding genes. Here we review the mitochondrial genetics and the clinical features of the mtDNA-related diseases.


Sign in / Sign up

Export Citation Format

Share Document